What are you looking for?
All Filters
Therapeutic Area
Therapeutic Area
Date Published
Date published
Group 2400.png

 

The simplicity of ONE monthly maintenance injection, regardless of dose1

 

Frame 427318914.png
Group 2405.png
Group 2406.png

  • axSpA: The recommended initial dose is 150 mg for both nr-axSpA and AS. followed by monthly maintenance dose.1

  • Each 300 mg dose is given as one subcutaneous injection of 300 mg or two injections of 150 mg.1

Cosentyx API

PDF
View

Footnotes:

AS=ankylosing spondylitis; axSpA=axial spondyloarthritis; nr-axSpA=non-radiographic axial spondyloarthritis; s.c.=subcutaneous.

References

  1. Egyptian Drug Authority (EDA) Cosentyx 150,300 mg leaflet approval date: 23/03/2025.

Approved by Egyptian Drug Authority:BF0424OA4792/092025. Invalidation date: 06/12/2026.
Kindly report any violated online promotional, educational and awareness material not having this message to The General administration for Regulation of Marketing & Advertising Materials at:
www.edaegypt.gov.eg

Cosentyx Rheumatology

BF0424OA4792/092025
06/12/2026

 

        

Adverse Events Reporting

We encourage using the following Electronic reporting tool for reporting into the safety database directly:
If the electronic reporting tool is not working - please use the following: https://www.report.novartis.com
1 - Generic Mailbox: [email protected]
2 - CISCO: +20 2 2 2861000: Press 3 for Adverse Events Reporting